Royalty Report: Drugs, Pharmaceuticals, Therapeutic – Collection: 3290

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3290

License Grant
The Korean Licensee has a right to exclusively negotiate a License for CX1846.
License Property
The Licensed compound and related product relate to CX1739.  CX1739 has shown some effectiveness in sleep apnea subjects.
Field of Use
The field of us includes neurodegenerative disorders including but not limited to Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis, as well as sleep apnea and respiratory depression.

IPSCIO Record ID: 28926

License Grant
The University grants to Licensee the exclusive license under the Patent Rights to make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the Field of Use. The Licensor also grants to Licensee the rights to issue exclusive or nonexclusive sublicenses. Field of Use means the use of Licensed Products for the treatment, prevention or palliation of any autoimmune disease, condition or indication, including, without limitation, multiple sclerosis.
License Property
The Licensor has conducted clinical trials of Estriol and certain additional intellectual property relating to the subject matter of the License Agreement has been created by the Licensor including the use of estrogens to control fatigue.

1) UCLA CASE NO. 2015-280: “Using Estrogens as Treatment to Improve Fatigue in Multiple Sclerosis and Other Neurodegenerative Diseases”

Provisional Patent Application No. 62/067,264 entitled, “Compositions and Methods for Treating Fatigue”, filed October 22, 2014 (UCLA Case No. 2015-280-1) by Dr. Rhonda R. Voskuhl, and assigned to The Regents.

2) UCLA CASE NO. 2015-282: “Using Estrogens as Treatments to Improve Depression Mood in Multiple Sclerosis and Other Neurodegenerative Diseases”

Provisional Patent Application No. 62/068,162 entitled, “Compositions and Methods for Treating Depression”, filed October 24, 2014 (UCLA Case No. 2015-282-1) by Dr. Rhonda R. Voskuhl, and assigned to The Regents.

3) UCLA CASE NO. 2015-605: “Estriol Blood Level for Maximizing Treatment in MS”

Provisional Patent Application No. 62/140,239 entitled, “Methods of Monitoring Estriol Therapy”, filed October 30, 2014 (UCLA Case No. 2015-605-1) by Dr. Rhonda R. Voskuhl, and assigned to The Regents.

4) UCLA CASE NO. 2015-606-1: “Sparing Gray Matter Atrophy In Ms Patients That Are Enhancing Lesion Negative”

Provisional Patent Application No. 62/140,245 entitled, “Methods of Providing Neuroprotective Therapy”, filed March 30, 2015 (UCLA Case No. 2015-606-1) by Dr. Rhonda R. Voskuhl, and assigned to The Regents.

Field of Use
“Field of Use” means the use of Licensed Products for the treatment, prevention or palliation of any autoimmune disease, condition or indication, including, without limitation, multiple sclerosis.

IPSCIO Record ID: 1809

License Grant
The Company has licensed proprietary rights for a series of compounds whose chemistry is based upon a purine, hypoxanthine, and for the use of these compounds in the treatment of neuroimmunologic disorders from the Chairman of the Board.
License Property
These compounds are bi-functional drugs that combine the ability of hypoxanthine to be absorbed rapidly into the body with the pharmacological activity of a second molecular component.  These second components were selected to provide a wide variety of potential therapeutic applications that act on the central nervous system to treat neurodegenerative diseases or conditions associated with Alzheimer’s disease, impairment associated with aging, Parkinson’s disease, stroke, spinal cord injuries, migraine and depression.  This patent expires on March 28, 2010.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.